임상시험 트래커

추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov

15건 표시

3상모집 예정· Opioid Consumption, Postoperative
Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery
협력: 버텍스
상세 →NCT07654296
3상모집 중· Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
리드: 버텍스
상세 →NCT07231419
3상모집 중· Type 1 Diabetes
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
리드: 버텍스
상세 →NCT06832410
3상모집 중단 (진행 중)· Diabetic Peripheral Neuropathic Pain
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
리드: 버텍스
상세 →NCT06696443
3상모집 중단 (진행 중)· Cystic Fibrosis
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
리드: 버텍스
상세 →NCT06460506
3상모집 중· Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
리드: 버텍스
상세 →NCT06628908
3상초청 등록· Cystic Fibrosis
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
리드: 버텍스
상세 →NCT05844449
3상모집 중단 (진행 중)· Cystic Fibrosis
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
리드: 버텍스
상세 →NCT05331183
3상모집 중단 (진행 중)· Cystic Fibrosis
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
리드: 버텍스
상세 →NCT05444257
3상모집 중· Beta-Thalassemia
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
리드: 버텍스
상세 →NCT05477563
3상모집 중단 (진행 중)· Cystic Fibrosis
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
리드: 버텍스
상세 →NCT05422222
3상모집 중단 (진행 중)· Beta-Thalassemia
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
리드: 버텍스
상세 →NCT05356195
3상모집 중단 (진행 중)· Sickle Cell Disease
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
리드: 버텍스
상세 →NCT05329649
3상모집 중· Diabetes Mellitus, Type 1
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
리드: 버텍스
상세 →NCT04786262
3상초청 등록· Beta-Thalassemia
A Long-term Follow-up Study in Participants Who Received CTX001
리드: 버텍스
상세 →NCT04208529

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.